{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:46:20Z","timestamp":1792082780815,"version":"4.4.0"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2018,12,6]]},"abstract":"<jats:sec><jats:title\/><jats:p>Diabetes mellitus is an emerging predator and affecting around 422 million adults worldwide. Higher levels of circulating insulin and increased pressure on the pancreas to produce insulin have been inferred as possible etiology for diabetes leading to a higher risk of pancreatic cancer. Out of several drug targets in hypoglycemic discovery, Dipeptidyl peptidase-IV (DPP-IV) has been considered an emerging target. It is a protease enzyme which inactivates incretin hormones i.e., Glucagonlike peptide 1 (GLP-1) and glucose-dependent insulin tropic polypeptide (GIP). Inhibition of DPP-4 results in the longer action of GLP-1 and GIP, therefore, DPP-4 inhibitors play an important role in maintaining glucose homeostasis. In comparison to early oral hypoglycemic, DPP-IV inhibitors are well tolerated and provide a better glycemic control over a longer period. These enzymes are expressed in a dimeric form on the surface of different cells such as prostate, liver and small intestinal epithelium cells. Disruption of the local signaling environment is an emerging factor in cancer development. Till date, not even a single DPP-IV inhibitor as anticancer has been developed. This review focuses on various features of the enzyme and their suitable inhibitors for target disease.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389557518666180423112154","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T12:02:47Z","timestamp":1524657767000},"page":"88-97","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer"],"prefix":"10.2174","volume":"19","author":[{"given":"Sourav","family":"De","sequence":"first","affiliation":[{"name":"Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhasis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Gupta College of Technological Sciences, Asansol-713301, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K. Ashok","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyankar","family":"Paira","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"Giovannucci E.","year":"2010","unstructured":"Giovannucci E, David MH, Michael CA, Richard MB, Susan MG, Laurel AH. Diabetes Care, Michael. P.; Regensteiner, J.G.; Douglas, Y. Diabetes and Cancer. A consensus report.,, 2010, 33,, 1674-1685,","journal-title":"Diabetes Care"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12777","volume":"81","author":"Guojing L.","year":"2016","unstructured":"Guojing L, Hong L, and Hongyun L. J Clin Pharmacol, Glucagon\u2010like peptide\u20101(GLP\u20101) receptor agonists: potential to reduce fracture risk in diabetic patients?,, 2016, 81,, 78-88,","journal-title":"J Clin Pharmacol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2337\/dc12-1609","volume":"36","author":"Chinmay S.M.","year":"2013","unstructured":"Chinmay SM, Christopher KR, Karen LJ, Michael H. Diabetes Care, ,, 2013, 36,, 1396-1405,","journal-title":"Diabetes Care"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","volume":"136","author":"Kieffer T.J.","year":"1995","unstructured":"Kieffer TJ, Mclntosh CH, Pederson RA. Endocrinology, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagonlike peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.,, 1995, 136,, 3585-3596,","journal-title":"Endocrinology"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(02)00039-3","volume":"107","author":"Meier J.J.","year":"2002","unstructured":"Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Regul Pept, Gastric inhibitory polypeptide: The neglected incretin revisited.,, 2002, 107,, 1-13,","journal-title":"Regul Pept"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/dmrr.357","volume":"19","author":"Egan J.M.","year":"2003","unstructured":"Egan JM, Bulotta A, Hui H, Perfetti R. Diabetes Metab Res Rev, GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.,, 2003, 19,, 115-123,","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2006-0028","volume":"27","author":"Murphy K.G.","year":"2006","unstructured":"Murphy KG, Dhillo WS, Bloom SR. Endocr Rev, Gut peptides in the regulation of food intake and energy homeostasis.,, 2006, 27,, 719-727,","journal-title":"Endocr Rev"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2741\/2797","volume":"13","author":"Mclntosh C.H.S.","year":"2008","unstructured":"Mclntosh CHS. Front Biosci Landmark Ed, Dipeptidyl peptidase IV inhibitors and diabetes therapy.,, 2008, 13,, 1753-1773,","journal-title":"Front Biosci Landmark Ed"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2174\/092986709788803114","volume":"16","author":"Matteucci E.","year":"2009","unstructured":"Matteucci E, Giampietro O. Curr Med Chem, Dipeptidyl peptidase-4 (CD26): knowing the functionbefore inhibiting the enzyme.,, 2009, 16,, 2943-2951,","journal-title":"Curr Med Chem"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dsx.2012.02.017","volume":"5","author":"Kshirsagar A.D.","year":"2011","unstructured":"Kshirsagar AD, Aggarwal AS, Harle UN, Deshpande AD. Diabetes Metab Syndr, DPP IV inhibitors: Successes, failures and future prospects.,, 2011, 5,, 105-112,","journal-title":"Diabetes Metab Syndr"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"24207","DOI":"10.1074\/jbc.273.37.24207","volume":"273","author":"Cheng H.C.","year":"1998","unstructured":"Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU. J Biol Chem, Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin.,, 1998, 273,, 24207-24215,","journal-title":"J Biol Chem"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1010930918055","volume":"18","author":"Pethiyagoda C.L.","year":"2000","unstructured":"Pethiyagoda CL, Welch DR, Fleming TP. Clin Exp Metastasis, Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.,, 2000, 18,, 391-400,","journal-title":"Clin Exp Metastasis"},{"key":"ref=13","first-page":"7204","volume":"61","author":"Aytac U.","year":"2001","unstructured":"Aytac U, Claret FX, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH. Cancer Res, Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)\/M checkpoint.,, 2001, 61,, 7204-7210,","journal-title":"Cancer Res"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.190.3.311","volume":"190","author":"Wesley U.V.","year":"1999","unstructured":"Wesley UV, Albino AP, Tiwari S, Houghton AN. J Exp Med, A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.,, 1999, 190,, 311-322,","journal-title":"J Exp Med"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jmb.2005.11.014","volume":"355","author":"Engel M.","year":"2006","unstructured":"Engel M, Hoffmann T, Manhart S, Heiser U, Chambre S, Huber R, Demuth HU, Bode W. J Mol Biol, Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV.,, 2006, 355,, 768-783,","journal-title":"J Mol Biol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/156802607780091064","volume":"7","author":"Kuhn B.","year":"2007","unstructured":"Kuhn B, Hennig M, Mattei P. Curr Top Med Chem, Molecular recognition of ligands in dipeptidyl peptidase IV.,, 2007, 7,, 609-619,","journal-title":"Curr Top Med Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/14756366.2014.1002402","volume":"30","author":"Watanabe Y.S.","year":"2015","unstructured":"Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M. J Enzyme Inhib Med Chem, Anagliptin, a potent dipeptidyl peptidase IV inhibitor: Its single-crystal structure and enzyme interactions.,, 2015, 30,, 981-988,","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/jm400658e","volume":"57","author":"Lucienne J.J.","year":"2014","unstructured":"Lucienne JJ. J Med Chem, Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?,, 2014, 57,, 2197-2212,","journal-title":"J Med Chem"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1021\/jm030626a","volume":"47","author":"Rotella D.P.","year":"2004","unstructured":"Rotella DP. J Med Chem, Novel Second-Generation approaches for the control of type 2 diabetes.,, 2004, 47,, 4111-4112,","journal-title":"J Med Chem"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm030628v","volume":"47","author":"Weber A.E.","year":"2004","unstructured":"Weber AE. J Med Chem, Dipeptidyl Peptidase IV Inhibitors for the treatment of Diabetes.,, 2004, 47,, 4135-4141,","journal-title":"J Med Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/CS20040302","volume":"108","author":"Gorrell M.D.","year":"2005","unstructured":"Gorrell MD. Clin Sci (Lond), Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders.,, 2005, 108,, 277-292,","journal-title":"Clin Sci (Lond)"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.4049\/jimmunol.162.8.4903","volume":"162","author":"Struyf S.","year":"1999","unstructured":"Struyf S, Proost P, Schols D. J Immunol, E.D.; Clercq, E.D.; Opdenakker, G.; Jean-Pierre, L.; Detheux, M.; Parmentier, M.; Meester, I.D.; Simmon, S.; Damme, J.V. CD26\/Dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.,, 1999, 162,, 4903-4909,","journal-title":"J Immunol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/ar1852","volume":"7","author":"Sedo A.","year":"2005","unstructured":"Sedo A, Duke-Cohan J. Arthritis Res Ther, S.; Balaziova, E.; Sedova, L, R. Dipeptidyl peptidase IV activity and\/or structure homologs: Contributing factors in the pathogenesis of rheumatoid arthritis?,, 2005, 7,, 253-269,","journal-title":"Arthritis Res Ther"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5562\/cca1863","volume":"85","author":"Detel D.","year":"2012","unstructured":"Detel D, Kehler T, Buljevic S, Pavacic I, Pucar LB, Varljen N, Varljen J. Croat Chem Acta, Is dipeptidyl peptidase IV (DPP IV) associated with inflammation present in human spondyloarthritides and rheumatoid arthritis.,, 2012, 85,, 231-238,","journal-title":"Croat Chem Acta"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/clinchem\/35.6.1016","volume":"35","author":"Gotoh H.","year":"1989","unstructured":"Gotoh H, Haglhara M, Nagateu T, Iwata H, Mlura T. Clin Chem, Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.,, 1989, 35,, 1016-1018,","journal-title":"Clin Chem"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","volume":"18","author":"Rossi D.","year":"2000","unstructured":"Rossi D, Zlotnik A. Annu Rev Immunol, The biology of chemokines and their receptors.,, 2000, 18,, 217-242,","journal-title":"Annu Rev Immunol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","volume":"48","author":"Kim D.","year":"2005","unstructured":"Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Sinha R, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. J Med Chem, (2R)-4-Oxo-4-[-(trifuloromethyl)- 5,6-dihydro [,2,]triazolo [,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluo-rophenyl) butan-2-amine: A potent orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.,, 2005, 48,, 141-151,","journal-title":"J Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","volume":"46","author":"Villhauer E.B.","year":"2003","unstructured":"Villhauer EB, Brinkman JA, Naderi GB, Burkey BNF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. J Med Chem, 1-3[(3-Hydroxy-1-adamantyl)amino] acetyl-2-cyano-(S)-pyrrolidine, a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.,, 2003, 46,, 2774-2789,","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/jm050261p","volume":"48","author":"Augeri D.J.","year":"2005","unstructured":"Augeri DJ, Robl JA, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG. J Med Chem, Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.,, 2005, 48,, 5025-5037,","journal-title":"J Med Chem"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/jm070104l","volume":"50","author":"Feng J.","year":"2007","unstructured":"Feng J, Zhang Z, Wallace M, Stafford J, Kaldor S, Kassel D, Navre M, Shi L. J Med Chem, Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.,, 2007, 50,, 2297-2300,","journal-title":"J Med Chem"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/jm701280z","volume":"50","author":"Eckhardt M.","year":"2007","unstructured":"Eckhardt M, Langkop E, Mark M, Tadayyon M, Thomas L, Nar H, Pfengle W, Guth B, Lotz R, Siegel P, Fuchs H, Himmelsbach E. J Med Chem, 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine- 2,6-dione (BI-1356) a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type-2 diabetes.,, 2007, 50,, 6450-6453,","journal-title":"J Med Chem"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2125.2009.03376.x","volume":"68","author":"Lim K.S.","year":"2009","unstructured":"Lim KS, Cho JY, Kim BH, Kim JR, Kim HS, Kim DK, Kim SH, Yim HJ, Lee SH, Shin SG, Jang IJ, Yu KS. Br J Clin Pharmacol, Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitors, after multiple dosing in healthy volunteers.,, 2009, 68,, 883-890,","journal-title":"Br J Clin Pharmacol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/dom.12042","volume":"15","author":"Yang S.J.","year":"2013","unstructured":"Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, Agarwal PK, Sosale A, Gandhi P, Dharmalingam M, Mohan V, Makesh U, Kim DM, Kim JA, Kim PK, Baik SH. Diabetes Obes Metab, A multicentre, multinational, randomized, placebo-controlled, doubleblind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.,, 2013, 15,, 410-416,","journal-title":"Diabetes Obes Metab"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lfs.2011.10.007","volume":"90","author":"Kim M.K.","year":"2012","unstructured":"Kim MK, Chae YN, Kim HD, Yang EK, Cho EJ, Choi SH, Cheong YH, Kim HS, Kim HJ, Jo YW, Son MH, Kim SH, Shin CY. Life Sci, DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.,, 2012, 90,, 21-29,","journal-title":"Life Sci"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2006.08.011","volume":"548","author":"Yasuda N.","year":"2000","unstructured":"Yasuda N, Nagakura T, Inoue T, Yamazaki K, Katsutani N, Takenaka O, Clark R, Matsuura F, Emori E, Yoshikawa S, Kira K, Ikuta H, Okada T, Saeki T, Asano O, Tanaka I. Eur J Pharmacol, E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo [,5-d]- pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase IV inhibitor.,, 2000, 548,, 181-187,","journal-title":"Eur J Pharmacol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/jm101236h","volume":"54","author":"Miyamoto Y.","year":"2011","unstructured":"Miyamoto Y, Banno Y, Yamashita T, Fujimoto T, Oi S, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Tsubotani S, Tani A, Sasaki M, Funami M, Amano M, Yamamoto Y, Aertgeerts K, Yano J. J Med Chem, A.H. Discovery of a 3-pyridylacetamide derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor.,, 2011, 54,, 831-850,","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2174\/156802608786413519","volume":"8","author":"Gwaltney S.L.","year":"2008","unstructured":"Gwaltney SL. Curr Top Med Chem, Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.,, 2008, 8,, 1545-1552,","journal-title":"Curr Top Med Chem"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bmc.2009.01.061","volume":"17","author":"M Pal.","year":"2009","unstructured":"M Pal. Bioorg Med Chem, Havale, S.H. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.,, 2009, 17,, 1783-1802,","journal-title":"Bioorg Med Chem"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.2174\/092986712802002491","volume":"19","author":"Liu Y.","year":"2012","unstructured":"Liu Y, Hu Y, Liu T. Curr Med Chem, Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.,, 2012, 19,, 3982-3999,","journal-title":"Curr Med Chem"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcp.2005.04.009","volume":"70","author":"Brandt L.","year":"2005","unstructured":"Brandt L, Joossens J, Chen X, Maes MB, Scharpe S, Lambeir AM. Biochem Pharmacol, Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-[(3-hydroxyadamantan- 1-yl) amino] acetyl-pyrrolidine-2-carbonitrile).,, 2005, 70,, 134-143,","journal-title":"Biochem Pharmacol"},{"key":"ref=41","first-page":"477","volume":"49","author":"Burkey B.F.","year":"2006","unstructured":"Burkey BF, Russell M, Wang K, Trappe J, Hughes TE. Diabetologia, Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9 (Abstract 07).,, 2006, 49,, 477-,","journal-title":"Diabetologia"},{"key":"ref=42","first-page":"8","volume":"35","author":"Brock C.M.","year":"2010","unstructured":"Brock CM. Diabetes, DPP-4 Inhibitors: What is their place in therapy?,, 2010, 35,, 8-13,","journal-title":"Diabetes"},{"key":"ref=43","first-page":"1","volume":"1","author":"Xourgia E.","year":"2017","unstructured":"Xourgia E, Papazafiropoulou AK, Karampousli E, Melidonis A. J Ren Med, DPP-4 Inhibitors vs. SGLT-2 Inhibitors.,, 2017, 1,, 1-7,","journal-title":"J Ren Med"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","volume":"411","author":"Liotta L.A.","year":"2001","unstructured":"Liotta LA, Kohn EC. Nature, The microenvironment of the tumour-host interface.,, 2001, 411,, 375-379,","journal-title":"Nature"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1096\/fasebj.9.9.7601338","volume":"9","author":"Vanhoof G.","year":"1995","unstructured":"Vanhoof G, Goossens F, Meester De. FASEB J, I.; Hendriks, D.; Scharpe, S. Proline motifs in peptides and their biological processing.,, 1995, 9,, 736-744,","journal-title":"FASEB J"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-4838(01)00278-3","volume":"1550","author":"\u0160edo A.","year":"2001","unstructured":"\u0160edo A, Malik R. Protein Struct Mol Enzymol, Dipeptidyl peptidase IV-like molecules: Homologous proteins or homologous activities? Biochim. Biophy. Acta (BBA)-.,, 2001, 1550,, 107-116,","journal-title":"Protein Struct Mol Enzymol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/0-306-46826-3_7","volume":"477","author":"Meester D.I.","year":"2000","unstructured":"Meester DI, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K, Scharpe S. Adv Experiment Med Biol, Natural substrates of dipeptidyl peptidase IV.,, 2000, 477,, 67-87,","journal-title":"Adv Experiment Med Biol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0014-5793(01)02982-9","volume":"507","author":"Lambeir A.M.","year":"2001","unstructured":"Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpe S, Meester DI. FEBS Lett, Kinetic study of the processing by dipeptidyl-peptidase IV\/CD26 of neuropeptides involved in pancreatic insulin secretion.,, 2001, 507,, 327-330,","journal-title":"FEBS Lett"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","volume":"85","author":"Mentlein R.","year":"1999","unstructured":"Mentlein R. Regulat Pept, Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides.,, 1999, 85,, 9-24,","journal-title":"Regulat Pept"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000058725","volume":"72","author":"Van. Damme J.","year":"1999","unstructured":"Van. Damme J. Chem Immunol, Struyf, S.; Wuyts, A.; Van.Coillie, E.; Menten, P.; Schols, D.; Sozzani, S.; Meester, De. I.; Proost, P. The role of CD26\/DPP IV in chemokine processing.,, 1999, 72,, 42-56,","journal-title":"Chem Immunol"},{"key":"ref=51","first-page":"1213","volume":"17","author":"Dang N.H.","year":"2002","unstructured":"Dang NH, Morimoto C. Histol Histopathol, CD26: An expanding role in immune regulation and cancer.,, 2002, 17,, 1213-1226,","journal-title":"Histol Histopathol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.190.3.301","volume":"190","author":"Iwata S.","year":"1999","unstructured":"Iwata S, Morimoto C. J Exper Med, CD26\/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation.,, 1999, 190,, 301-306,","journal-title":"J Exper Med"},{"key":"ref=53","first-page":"2753","volume":"62","author":"Kajiyama H.","year":"2002","unstructured":"Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S. Cancer Res, Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma.,, 2002, 62,, 2753-2757,","journal-title":"Cancer Res"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/hep.510270407","volume":"27","author":"Fiore M.","year":"1998","unstructured":"Fiore M, de Filippo S, Pozzi N, Tamasi S, Pignata C. Hepatology, Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells.,, 1998, 27,, 934-942,","journal-title":"Hepatology"},{"key":"ref=55","first-page":"2031","volume":"7","author":"Ho L.","year":"2001","unstructured":"Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH. Clin Cancer Res, In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.,, 2001, 7,, 2031-2040,","journal-title":"Clin Cancer Res"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1042\/bj3550397","volume":"355","author":"Gonzalez-Gronow M.","year":"2001","unstructured":"Gonzalez-Gronow M, Grenett HE, Weber MR, Gawdi G, Pizzo SV. Biochem J, Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.,, 2001, 355,, 397-407,","journal-title":"Biochem J"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.4049\/jimmunol.167.12.6745","volume":"167","author":"Ohnuma K.","year":"2001","unstructured":"Ohnuma K, Munakata Y, Ishii T, Iwata S, Kobayashi S, Hosono O, Kawasaki H, Dang NH, Morimoto C. J Immunol, Soluble CD26\/dipeptidyl peptidase IV induces T-cell proliferation through CD86 up-regulation on APCs.,, 2001, 167,, 6745-6755,","journal-title":"J Immunol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"Scanlan M.J.","year":"1994","unstructured":"Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ. Proc Nat Acad Sci USA, Molecular cloning of fibroblast activation protein. a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.,, 1994, 91,, 5657-5661,","journal-title":"Proc Nat Acad Sci USA"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/161481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T08:29:11Z","timestamp":1693643351000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/161481\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,12,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557518666180423112154","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2016-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}